Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 3/2021

Open Access 01-10-2021 | Antiphospholipid Syndrome

Association between plasmatic oxidative stress and thrombosis in primary antiphospholipid syndrome

Authors: Camila O. Vaz, Bruna M Mazetto, Pedro Eduardo N. S. Vasconcelos, Larissa B. Bastos, Maria Aparecida Cursino, Júlia Coelho França Quintanilha, Gabriela Lisiane Tripiquia Vechiatto Mesquita, Ana Paula R. Santos, Bruna Cardoso Jacintho, José Diogo Oliveira, Joyce Annichino-Bizzachi, Fernanda A. Orsi

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2021

Login to get access

Abstract

Antiphospholipid antibodies induce a pro-inflammatory and hypercoagulable state that lead to increased risk of thrombosis. Whether oxidative damage contributes thrombosis risk is a matter of debate. We evaluated the association between oxidative stress and thrombosis in primary antiphospholipid syndrome (t-PAPS). Plasma total antioxidant capacity and the levels of malondialdehyde (TBARs), carbonyl protein, and 8-isoprostane in plasma were determined in a group of patients with t-PAPS and in individuals without a history of thrombosis (controls) using commercial ELISA assays. The levels of these plasma markers of oxidative stress were compared between t-PAPS and controls using Mann–Whitney test. A total of 70 patients with t-PAPS and 74 controls were included. Overall, measurements of all plasma oxidative stress markers were similar between t-PAPS patients and controls. In a subgroup analysis, patients with t-PAPS and arterial thrombosis had a higher antioxidant capacity as compared to controls. Thrombotic PAPS was not associated with increased levels of oxidative stress markers, in comparison with individuals without thrombosis. Even though it is not possible to rule out that a mild oxidative damage, not detected by plasma markers, occurs in t-PAPS, our results suggest that measuring plasma oxidative stress markers has limited clinical relevance in t-PAPS.
Literature
1.
go back to reference Hughes G (2007) Hughes syndrome: the antiphospholipid syndrome–a clinical overview. Clin Rev Allergy Immunol 32(1):3–12CrossRef Hughes G (2007) Hughes syndrome: the antiphospholipid syndrome–a clinical overview. Clin Rev Allergy Immunol 32(1):3–12CrossRef
4.
go back to reference Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quere I, Hachulla E, Vasconcelos C, Roch B, Fernandez-Nebro A, Boffa MC, Hughes GR, Ingelmo M (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46(4):1019–1027. https://doi.org/10.1002/art.10187CrossRefPubMed Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Lakos G, Tincani A, Kontopoulou-Griva I, Galeazzi M, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, Quere I, Hachulla E, Vasconcelos C, Roch B, Fernandez-Nebro A, Boffa MC, Hughes GR, Ingelmo M (2002) Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46(4):1019–1027. https://​doi.​org/​10.​1002/​art.​10187CrossRefPubMed
6.
go back to reference Shi W, Chong BH, Chesterman CN (1993) Beta 2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants. Blood 81(5):1255–1262CrossRef Shi W, Chong BH, Chesterman CN (1993) Beta 2-glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: differences with lupus anticoagulants. Blood 81(5):1255–1262CrossRef
7.
go back to reference Perez-Sanchez C, Ruiz-Limon P, Aguirre MA, Bertolaccini ML, Khamashta MA, Rodriguez-Ariza A, Segui P, Collantes-Estevez E, Barbarroja N, Khraiwesh H, Gonzalez-Reyes JA, Villalba JM, Velasco F, Cuadrado MJ, Lopez-Pedrera C (2012) Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q(10) treatment. Blood 119(24):5859–5870. https://doi.org/10.1182/blood-2011-12-400986CrossRefPubMed Perez-Sanchez C, Ruiz-Limon P, Aguirre MA, Bertolaccini ML, Khamashta MA, Rodriguez-Ariza A, Segui P, Collantes-Estevez E, Barbarroja N, Khraiwesh H, Gonzalez-Reyes JA, Villalba JM, Velasco F, Cuadrado MJ, Lopez-Pedrera C (2012) Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q(10) treatment. Blood 119(24):5859–5870. https://​doi.​org/​10.​1182/​blood-2011-12-400986CrossRefPubMed
8.
go back to reference Alves JD, Grima B (2003) Oxidative stress in systemic lupus erythematosus and antiphospholipid syndrome: a gateway to atherosclerosis. Curr Rheumatol Rep 5(5):383–390CrossRef Alves JD, Grima B (2003) Oxidative stress in systemic lupus erythematosus and antiphospholipid syndrome: a gateway to atherosclerosis. Curr Rheumatol Rep 5(5):383–390CrossRef
12.
go back to reference Charakida M, Besler C, Batuca JR, Sangle S, Marques S, Sousa M, Wang G, Tousoulis D, Delgado Alves J, Loukogeorgakis SP, Mackworth-Young C, D’Cruz D, Luscher T, Landmesser U, Deanfield JE (2009) Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA 302(11):1210–1217. https://doi.org/10.1001/jama.2009.1346CrossRefPubMed Charakida M, Besler C, Batuca JR, Sangle S, Marques S, Sousa M, Wang G, Tousoulis D, Delgado Alves J, Loukogeorgakis SP, Mackworth-Young C, D’Cruz D, Luscher T, Landmesser U, Deanfield JE (2009) Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA 302(11):1210–1217. https://​doi.​org/​10.​1001/​jama.​2009.​1346CrossRefPubMed
14.
18.
go back to reference Stanisavljevic N, Stojanovich L, Marisavljevic D, Djokovic A, Dopsaj V, Kotur-Stevuljevic J, Martinovic J, Memon L, Radovanovic S, Todic B, Lisulov D (2016) Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome patients. Clin Rheumatol 35(10):2485–2493. https://doi.org/10.1007/s10067-016-3369-8CrossRefPubMed Stanisavljevic N, Stojanovich L, Marisavljevic D, Djokovic A, Dopsaj V, Kotur-Stevuljevic J, Martinovic J, Memon L, Radovanovic S, Todic B, Lisulov D (2016) Lipid peroxidation as risk factor for endothelial dysfunction in antiphospholipid syndrome patients. Clin Rheumatol 35(10):2485–2493. https://​doi.​org/​10.​1007/​s10067-016-3369-8CrossRefPubMed
19.
go back to reference Sciascia S, Roccatello D, Bertero MT, Di Simone D, Cosseddu D, Vaccarino A, Bazzan M, Rossi D, Garcia-Fernandez C, Ceberio L, Stella S, Menegatti E, Baldovino S (2012) 8-isoprostane, prostaglandin E2, C-reactive protein and serum amyloid A as markers of inflammation and oxidative stress in antiphospholipid syndrome: a pilot study. Inflamm Res 61(8):809–816. https://doi.org/10.1007/s00011-012-0468-0CrossRefPubMed Sciascia S, Roccatello D, Bertero MT, Di Simone D, Cosseddu D, Vaccarino A, Bazzan M, Rossi D, Garcia-Fernandez C, Ceberio L, Stella S, Menegatti E, Baldovino S (2012) 8-isoprostane, prostaglandin E2, C-reactive protein and serum amyloid A as markers of inflammation and oxidative stress in antiphospholipid syndrome: a pilot study. Inflamm Res 61(8):809–816. https://​doi.​org/​10.​1007/​s00011-012-0468-0CrossRefPubMed
25.
go back to reference Fisher-Wellman K, Bell HK, Bloomer RJ (2009) Oxidative stress and antioxidant defense mechanisms linked to exercise during cardiopulmonary and metabolic disorders. Oxid Med Cell Longev 2(1):43–51CrossRef Fisher-Wellman K, Bell HK, Bloomer RJ (2009) Oxidative stress and antioxidant defense mechanisms linked to exercise during cardiopulmonary and metabolic disorders. Oxid Med Cell Longev 2(1):43–51CrossRef
Metadata
Title
Association between plasmatic oxidative stress and thrombosis in primary antiphospholipid syndrome
Authors
Camila O. Vaz
Bruna M Mazetto
Pedro Eduardo N. S. Vasconcelos
Larissa B. Bastos
Maria Aparecida Cursino
Júlia Coelho França Quintanilha
Gabriela Lisiane Tripiquia Vechiatto Mesquita
Ana Paula R. Santos
Bruna Cardoso Jacintho
José Diogo Oliveira
Joyce Annichino-Bizzachi
Fernanda A. Orsi
Publication date
01-10-2021
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 3/2021
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-021-02509-0

Other articles of this Issue 3/2021

Journal of Thrombosis and Thrombolysis 3/2021 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.